'Target pediatric specific conditions' diaporamas de présentation

Reports and Intelligence: Pediatric drug development

Although pediatrics represent around two-fifths of the global population the market for pediatric medicines remains relatively small (accounting for <10% of global pharmaceutical sales). Until pediatric legislation was introduced in the US (1997) and EU (2007) there has been little incentive for the pharma industry to evaluate drugs in children due to the low medical need of chronic illnesses and the high off-label use of generic drugs (Milne & Bruss, 2008). Detailed report at: http://www.reportsandintelligence.com/pediatric-drug-development-regulatory-challenges-and-commercial-opportunities-market

256 views • 7 slides